Lab Manager | Run Your Lab Like a Business

Salix Pharmaceuticals acquires PEPCID Oral Suspension

Salix Pharmaceuticals, Ltd. today announced that it has purchased the U.S. prescription pharmaceutical product rights to PEPCID Oral Suspension and DIURIL Oral Suspension from Merck & Co., Inc.

PEPCID Oral Suspens

Register for free to listen to this article
Listen with Speechify
0:00
5:00

Salix Pharmaceuticals, Ltd. today announced that it has purchased the U.S. prescription pharmaceutical product rights to PEPCID Oral Suspension and DIURIL Oral Suspension from Merck & Co., Inc.

PEPCID Oral Suspension is a prescription pharmaceutical product for several gastrointestinal indications including the treatment of duodenal ulcer, benign gastric ulcer and gastroesophageal reflux disease. Under the terms of the agreement, Salix will make a $55 million up-front payment and up to $6 million in potential sales-based milestone payments to Merck.

Salix also announced today that it has entered into a credit facility with Bank of America, N.A. for up to $100 million to help finance the transaction and for working capital, capital expenditures, other acquisitions and general corporate purposes. Salix has borrowed approximately $15 million at this time. Outstanding amounts generally bear interest at the option of Salix at the British Bankers Association LIBOR Rate or a base rate, in each case plus an applicable margin of between 1.00 percent and 1.75 percent for LIBOR Rate loans and 0.00 percent and 0.75 percent for base rate loans, each based on consolidated leverage. The facility also includes standard covenants. A copy will be filed with the SEC as an exhibit to our Form 8-K.

Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases. Salix's strategy is to in-license late-stage or marketed proprietary therapeutic drugs, complete any required development and regulatory submission of these products, and market them through the Company's 150-member gastroenterology specialty sales and marketing team.

Salix trades on the Nasdaq National Market under the ticker symbol "SLXP".